🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

Recruitingn/aAges 18 Years - anyAllAbbVie
NCT06764706 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe UC in real-world clinical practice. Risankizumab is an approved drug for treating participants with ulcerative colitis. Approximately 200 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately multiple sites across Germany and Austria. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 52 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants with an endoscopically confirmed diagnosis of moderate to severe ulcerative colitis. * Participants initiating risankizumab at the investigator's discretion as part of their routine clinical care; the decision to administer risankizumab must be made prior to and independent of documentation for the study and according to the approved local label. Exclusion Criteria: * Participants previously exposed risankizumab * Participants who are currently participating in interventional research (not including noninterventional studies, post-marketing observational study (PMOS), or registry participation).
💊

What it tests

  • Not listed
📍

Where

57 sites
Universitaetsklinikum Heidelberg /ID# 275906
Heidelberg, Germany
Klinikum Ernst Von Bergmann /ID# 278268
Potsdam, Germany
Private Practice Dr. Katharina Pfeifer /ID# 286373
Wriezen, Germany
Private Practice - Dr. Kempelmann /ID# 275726
Tostedt, Germany
Gastroenterologische Schwerpunktpraxis - Hannover /ID# 276701
Hanover, Germany
Praxis fuer Gastroenterologie - Schwerin /ID# 275946
Schwerin, Germany
Medizinisches Versorgungszentrum Ahaus /ID# 280966
Ahaus, Germany
Gastropraxis Bochum /ID# 281375
Bochum, Germany

…and 49 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy